Target intelligence / Profile preview

Ubiquitin-proteasome system components (UPS) (UPS)

Target
UPS
Molecular classification
Enzyme, E3 ubiquitin ligase, E2 ubiquitin-conjugating enzyme, E1 ubiquitin-activating enzyme, Deubiquitinating enzyme, Proteasome
01

Overview

The ubiquitination pathway, primarily known as the ubiquitin-proteasome system (UPS), is a fundamental cellular mechanism for regulated protein degradation and signal transduction (Source: Glickman & Ciechanover, 2002, Physiological Reviews). It involves a three-step enzymatic cascade: E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin-ligating) enzymes, which covalently attach ubiquitin to target substrates (Source: UniProt, "Ubiquitin-proteasome system"). This modification often serves as a signal for the 26S proteasome to degrade the protein, though it also regulates DNA repair, endocytosis, and immune signaling (Source: Mansour, 2018, Cell Communication and Signaling). Dysregulation of UPS components is central to the pathogenesis of various cancers, where it may lead to the degradation of tumor suppressors like p53, and neurodegenerative diseases such as Parkinson's, characterized by the failure to clear misfolded proteins (Source: Popovic et al., 2014, Nature Medicine). Therapeutic targeting of the UPS has yielded significant clinical success, notably with proteasome inhibitors like bortezomib for multiple myeloma and E3 ligase modulators like lenalidomide (Source: FDA, 2003, 2005). Emerging modalities such as Proteolysis Targeting Chimeras (PROTACs) further exploit this pathway to achieve targeted protein degradation of previously "undruggable" targets (Source: Arvinas, 2023).

Other names
Ubiquitination pathway componentsUbiquitin-proteasome systemUPSUbiquitin-mediated proteolysis pathwayProtein ubiquitination pathway
02

Mechanism of action

Proteasome inhibition, E3 ligase modulation (molecular glues), Targeted protein degradation (PROTACs), Deubiquitinase (DUB) inhibition

03

Biological functions

Protein degradationCell cycle regulationDNA repairSignal transductionApoptosisImmune responseProtein quality control
04

Disease associations

CancerNeurodegenerative diseaseInflammationAutoimmune diseaseMuscle wasting
05

Safety considerations

Peripheral neuropathyMyelosuppression (thrombocytopenia, neutropenia)TeratogenicityGastrointestinal toxicityOff-target protein degradation
06

Interacting drugs

Bortezomib

8 more in the full profile.

07

Biomarkers

Cereblon (CRBN) expressionMDM2 amplificationp53 mutation statusPolyubiquitin chain levelsProteasome activity

Beyond the preview

Go deeper on Ubiquitin-proteasome system components (UPS) (UPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-proteasome system components (UPS) (UPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call